ABSTRACT
The determination of human serum cholinesterase (EC 3.1.1.8) is frequently requested to detect patients with atypical forms of the enzyme which reacts abnormally with succinylcholine (suxamethonium), employed as a neuromuscular blocking agent. Usually, for biochemical identification of succinylcholine sensitive individuals the standard reaction is run with and without the inhibitors, notably dibucaine. A new test for direct determination of succinylcholine sensitive individuals which use a substrate analogue of succinylcholine was applied to a automated instrument. The linearity, precision, recovery, interference and correlation of the method have been evaluated. We have estimated the reference intervals for a population of 364 healthy subjects subdivided for sex, three atypical homozygotes and two atypical heterozygotes. On the basis of analytical performance we can conclude that this test may offer a further parameter for preoperative screening of individuals with an abnormal response to the muscle relaxant succinylcholine, thus avoiding the determination of genotype by measurement of dibucaine number.
Subject(s)
Cholinesterases/blood , Succinylcholine , Bilirubin/blood , Cholinesterases/classification , Evaluation Studies as Topic , Female , Hemoglobins/analysis , Humans , Male , Reagent Kits, DiagnosticABSTRACT
A new method to measure serum glycosylated proteins as index of diabetic control is evaluated. Precision, recovery and interference tests have been evaluated. A good correlation of fructosamine values with glycosylated haemoglobin and glucose in normal and diabetic patients was found. The analytical performance and its simple application to automated instruments make this test suitable for monitoring diabetes mellitus and for assessing intermediate-term control of blood glucose.
